Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01458 |
| Species: | Homo sapiens |
| Position : | chr11:1985000-2005000 |
| Year: | 2025 |
| Title: | Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | hepatocellular carcinoma |
| PMID: | 39799319 |
| MONDO: | MONDO:0007256 |
| Tissue: | Liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | Huh-7 |
| CVCL ID: | CVCL_0336 |
| Cell Type: | hepatocellular carcinoma cell |
| Cell Ontology ID: | CL:0000182 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, 3C-RT-qPCR, ChIP-RT-qPCR, qRT-PCR, Western blot |
| Target gene : | IGF2 |
| TF name : |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|